Switch to:
Also traded in: Germany, Mexico

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.03
AGN's Cash to Debt is ranked lower than
98% of the 761 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.46 vs. AGN: 0.03 )
Ranked among companies with meaningful Cash to Debt only.
AGN' s Cash to Debt Range Over the Past 10 Years
Min: 0.02  Med: 0.54 Max: 43.62
Current: 0.03
0.02
43.62
Equity to Asset 0.56
AGN's Equity to Asset is ranked lower than
59% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.62 vs. AGN: 0.56 )
Ranked among companies with meaningful Equity to Asset only.
AGN' s Equity to Asset Range Over the Past 10 Years
Min: 0.25  Med: 0.62 Max: 0.93
Current: 0.56
0.25
0.93
F-Score: 6
Z-Score: 0.98
M-Score: -2.45
WACC vs ROIC
11.25%
-1.45%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) -12.96
AGN's Operating margin (%) is ranked lower than
80% of the 707 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.77 vs. AGN: -12.96 )
Ranked among companies with meaningful Operating margin (%) only.
AGN' s Operating margin (%) Range Over the Past 10 Years
Min: -21.33  Med: 9.40 Max: 14.13
Current: -12.96
-21.33
14.13
Net-margin (%) 21.42
AGN's Net-margin (%) is ranked higher than
87% of the 710 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.28 vs. AGN: 21.42 )
Ranked among companies with meaningful Net-margin (%) only.
AGN' s Net-margin (%) Range Over the Past 10 Years
Min: -22.48  Med: 5.41 Max: 9.4
Current: 21.42
-22.48
9.4
ROE (%) 5.65
AGN's ROE (%) is ranked lower than
56% of the 739 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.27 vs. AGN: 5.65 )
Ranked among companies with meaningful ROE (%) only.
AGN' s ROE (%) Range Over the Past 10 Years
Min: -23.54  Med: 6.12 Max: 12.05
Current: 5.65
-23.54
12.05
ROA (%) 3.21
AGN's ROA (%) is ranked lower than
53% of the 763 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.85 vs. AGN: 3.21 )
Ranked among companies with meaningful ROA (%) only.
AGN' s ROA (%) Range Over the Past 10 Years
Min: -13.02  Med: 3.51 Max: 6.67
Current: 3.21
-13.02
6.67
ROC (Joel Greenblatt) (%) -45.56
AGN's ROC (Joel Greenblatt) (%) is ranked lower than
80% of the 755 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.64 vs. AGN: -45.56 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
AGN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -37.89  Med: 22.91 Max: 39.38
Current: -45.56
-37.89
39.38
Revenue Growth (3Y)(%) 17.90
AGN's Revenue Growth (3Y)(%) is ranked lower than
77% of the 593 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.10 vs. AGN: 17.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
AGN' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 6.4  Med: 17.55 Max: 40.4
Current: 17.9
6.4
40.4
EBITDA Growth (3Y)(%) -3.70
AGN's EBITDA Growth (3Y)(%) is ranked lower than
66% of the 543 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.90 vs. AGN: -3.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
AGN' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -4.4  Med: 5.60 Max: 33.2
Current: -3.7
-4.4
33.2
» AGN's 10-Y Financials

Financials (Next Earnings Date: 2016-05-10)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2015

AGN Guru Trades in Q2 2015

John Burbank 249,857 sh (New)
Louis Moore Bacon 19,346 sh (New)
Chris Davis 2,100 sh (New)
Alan Fournier 220,000 sh (New)
John Keeley 660 sh (New)
Howard Marks 71,000 sh (New)
Lee Ainslie 1,459,560 sh (+361.61%)
Paul Tudor Jones 5,937 sh (+169.86%)
John Paulson 7,174,200 sh (+27.18%)
Steve Mandel 2,297,966 sh (+25.41%)
Pioneer Investments 711,397 sh (+19.99%)
Diamond Hill Capital 4,890 sh (+19.27%)
Andreas Halvorsen 6,804,034 sh (+11.44%)
Ken Fisher 3,580 sh (+10.73%)
RS Investment Management 415,082 sh (+7.66%)
Mario Gabelli 37,286 sh (+6.07%)
Private Capital 165,927 sh (+4.45%)
Vanguard Health Care Fund 9,038,107 sh (unchged)
John Griffin 1,466,000 sh (unchged)
Larry Robbins 1,982,709 sh (unchged)
Bernard Horn 20,689 sh (unchged)
Steven Cohen Sold Out
Bill Ackman Sold Out
Dodge & Cox 1,601 sh (-0.06%)
Jana Partners 1,618,385 sh (-0.21%)
Scott Black 39,110 sh (-0.86%)
Leon Cooperman 922,375 sh (-1.19%)
First Eagle Investment 1,546,324 sh (-1.73%)
Daniel Loeb 3,300,000 sh (-7.69%)
Julian Robertson 44,500 sh (-38.62%)
George Soros 159,338 sh (-61.82%)
Jeremy Grantham 1,029 sh (-99.61%)
» More
Q3 2015

AGN Guru Trades in Q3 2015

Jim Simons 53,969 sh (New)
Kyle Bass 17,813 sh (New)
Ruane Cunniff 1,103,395 sh (New)
First Pacific Advisors 30,580 sh (New)
Wallace Weitz 187,607 sh (New)
Paul Singer 663,000 sh (New)
Jeremy Grantham 819,684 sh (+79558.31%)
Diamond Hill Capital 66,793 sh (+1265.91%)
George Soros 774,566 sh (+386.12%)
Signature Select Canadian Fund 35,400 sh (+233.96%)
Alan Fournier 652,100 sh (+196.41%)
Paul Tudor Jones 11,317 sh (+90.62%)
Julian Robertson 59,700 sh (+34.16%)
Jana Partners 1,886,931 sh (+16.59%)
Steve Mandel 2,607,655 sh (+13.48%)
John Griffin 1,630,842 sh (+11.24%)
Daniel Loeb 3,669,000 sh (+11.18%)
First Eagle Investment 1,671,156 sh (+8.07%)
Andreas Halvorsen 7,202,384 sh (+5.85%)
Private Capital 169,620 sh (+2.23%)
Vanguard Health Care Fund 9,190,927 sh (+1.69%)
John Paulson 7,182,000 sh (+0.11%)
Bernard Horn 20,689 sh (unchged)
Chris Davis 2,100 sh (unchged)
David Carlson 340,000 sh (unchged)
First Eagle Investment 335 sh (unchged)
John Keeley Sold Out
Howard Marks Sold Out
Louis Moore Bacon Sold Out
John Burbank Sold Out
Pioneer Investments 692,942 sh (-2.59%)
Scott Black 38,015 sh (-2.80%)
Ken Fisher 3,185 sh (-11.03%)
Leon Cooperman 811,635 sh (-12.01%)
RS Investment Management 358,388 sh (-13.66%)
Mario Gabelli 31,862 sh (-14.55%)
Larry Robbins 1,523,609 sh (-23.16%)
Dodge & Cox 1,100 sh (-31.29%)
Lee Ainslie 580,418 sh (-60.23%)
» More
Q4 2015

AGN Guru Trades in Q4 2015

Ron Baron 11,752 sh (New)
David Tepper 150,000 sh (New)
David Einhorn 410,000 sh (New)
Louis Moore Bacon 6,816 sh (New)
Eric Mindich 948,569 sh (New)
Steven Cohen 73,200 sh (New)
John Hussman 5,000 sh (New)
Joel Greenblatt 42,240 sh (New)
Paul Tudor Jones 50,857 sh (+349.39%)
Jim Simons 206,701 sh (+283.00%)
Paul Singer 2,020,500 sh (+204.75%)
Daniel Loeb 5,400,000 sh (+47.18%)
John Griffin 2,000,000 sh (+22.64%)
Vanguard Health Care Fund 10,962,347 sh (+19.27%)
Alan Fournier 765,800 sh (+17.44%)
Lee Ainslie 679,930 sh (+17.14%)
Mario Gabelli 33,473 sh (+5.06%)
Wallace Weitz 196,170 sh (+4.56%)
Ken Fisher 3,306 sh (+3.80%)
Paul Tudor Jones 20,000 sh (unchged)
Paul Singer 770,000 sh (unchged)
David Carlson 340,000 sh (unchged)
Bernard Horn 20,689 sh (unchged)
Samuel Isaly 343,025 sh (unchged)
Steve Mandel Sold Out
Chris Davis Sold Out
Kyle Bass Sold Out
Dodge & Cox Sold Out
Julian Robertson Sold Out
Larry Robbins Sold Out
RS Investment Management 352,778 sh (-1.57%)
Ruane Cunniff 1,085,870 sh (-1.59%)
Private Capital 166,017 sh (-2.12%)
Leon Cooperman 781,780 sh (-3.68%)
Pioneer Investments 632,600 sh (-8.71%)
Diamond Hill Capital 57,154 sh (-14.43%)
Andreas Halvorsen 5,978,075 sh (-17.00%)
First Pacific Advisors 24,100 sh (-21.19%)
John Paulson 5,532,600 sh (-22.97%)
Jana Partners 1,164,663 sh (-38.28%)
George Soros 365,390 sh (-52.83%)
First Eagle Investment 669,995 sh (-59.91%)
Jeremy Grantham 281,993 sh (-65.60%)
Scott Black 7,453 sh (-80.39%)
» More
Q1 2016

AGN Guru Trades in Q1 2016

Jerome Dodson 40,000 sh (New)
Ken Fisher 3,225 sh (-2.45%)
Samuel Isaly 341,025 sh (-0.58%)
» More
» Details

Insider Trades

Latest Guru Trades with AGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Allergan PLC

SymbolPriceYieldDescription
AGNPRA811.496.735 1/2 % Cum.Conv.Pref.Shs 2015-1.3.18 Series -A-

Ratios

vs
industry
vs
history
P/E(ttm) 24.47
AGN's P/E(ttm) is ranked higher than
53% of the 540 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 28.10 vs. AGN: 24.47 )
Ranked among companies with meaningful P/E(ttm) only.
AGN' s P/E(ttm) Range Over the Past 10 Years
Min: 11.01  Med: 27.53 Max: 485.71
Current: 24.47
11.01
485.71
Forward P/E 12.14
AGN's Forward P/E is ranked higher than
64% of the 69 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.85 vs. AGN: 12.14 )
Ranked among companies with meaningful Forward P/E only.
N/A
Price/Owner Earnings (ttm) 113.46
AGN's Price/Owner Earnings (ttm) is ranked lower than
62% of the 261 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 32.99 vs. AGN: 113.46 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
AGN' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 8.13  Med: 18.19 Max: 574.91
Current: 113.46
8.13
574.91
P/B 1.19
AGN's P/B is ranked higher than
81% of the 727 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.94 vs. AGN: 1.19 )
Ranked among companies with meaningful P/B only.
AGN' s P/B Range Over the Past 10 Years
Min: 1.03  Med: 1.75 Max: 5.9
Current: 1.19
1.03
5.9
P/S 3.72
AGN's P/S is ranked lower than
66% of the 691 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.78 vs. AGN: 3.72 )
Ranked among companies with meaningful P/S only.
AGN' s P/S Range Over the Past 10 Years
Min: 0.99  Med: 1.84 Max: 5.5
Current: 3.72
0.99
5.5
PFCF 21.61
AGN's PFCF is ranked higher than
59% of the 194 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 29.93 vs. AGN: 21.61 )
Ranked among companies with meaningful PFCF only.
AGN' s PFCF Range Over the Past 10 Years
Min: 6.62  Med: 14.78 Max: 36.71
Current: 21.61
6.62
36.71
POCF 18.46
AGN's POCF is ranked lower than
52% of the 253 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 18.08 vs. AGN: 18.46 )
Ranked among companies with meaningful POCF only.
AGN' s POCF Range Over the Past 10 Years
Min: 5.97  Med: 12.09 Max: 31.19
Current: 18.46
5.97
31.19
EV-to-EBIT -47.18
AGN's EV-to-EBIT is ranked lower than
99.99% of the 526 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.82 vs. AGN: -47.18 )
Ranked among companies with meaningful EV-to-EBIT only.
AGN' s EV-to-EBIT Range Over the Past 10 Years
Min: -278.4  Med: 13.60 Max: 102
Current: -47.18
-278.4
102
EV-to-EBITDA 49.98
AGN's EV-to-EBITDA is ranked lower than
81% of the 551 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.62 vs. AGN: 49.98 )
Ranked among companies with meaningful EV-to-EBITDA only.
AGN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -224.1  Med: 9.80 Max: 105.7
Current: 49.98
-224.1
105.7
Shiller P/E 464.35
AGN's Shiller P/E is ranked lower than
100% of the 140 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 45.65 vs. AGN: 464.35 )
Ranked among companies with meaningful Shiller P/E only.
AGN' s Shiller P/E Range Over the Past 10 Years
Min: 14.67  Med: 48.40 Max: 841.89
Current: 464.35
14.67
841.89
Current Ratio 2.05
AGN's Current Ratio is ranked lower than
87% of the 656 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.41 vs. AGN: 2.05 )
Ranked among companies with meaningful Current Ratio only.
AGN' s Current Ratio Range Over the Past 10 Years
Min: 1.31  Med: 2.93 Max: 9.8
Current: 2.05
1.31
9.8
Quick Ratio 1.89
AGN's Quick Ratio is ranked lower than
78% of the 656 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. AGN: 1.89 )
Ranked among companies with meaningful Quick Ratio only.
AGN' s Quick Ratio Range Over the Past 10 Years
Min: 0.78  Med: 2.00 Max: 8.82
Current: 1.89
0.78
8.82
Days Inventory 121.12
AGN's Days Inventory is ranked higher than
53% of the 659 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 113.44 vs. AGN: 121.12 )
Ranked among companies with meaningful Days Inventory only.
AGN' s Days Inventory Range Over the Past 10 Years
Min: 108.18  Med: 121.54 Max: 133.19
Current: 121.12
108.18
133.19
Days Sales Outstanding 47.96
AGN's Days Sales Outstanding is ranked higher than
74% of the 610 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.18 vs. AGN: 47.96 )
Ranked among companies with meaningful Days Sales Outstanding only.
AGN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 39.05  Med: 67.09 Max: 92.81
Current: 47.96
39.05
92.81
Days Payable 21.76
AGN's Days Payable is ranked lower than
91% of the 585 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.90 vs. AGN: 21.76 )
Ranked among companies with meaningful Days Payable only.
AGN' s Days Payable Range Over the Past 10 Years
Min: 26.19  Med: 61.78 Max: 140.62
Current: 21.76
26.19
140.62

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.08
AGN's Price/Projected FCF is ranked higher than
85% of the 298 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.83 vs. AGN: 1.08 )
Ranked among companies with meaningful Price/Projected FCF only.
AGN' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.6  Med: 1.14 Max: 3.29
Current: 1.08
0.6
3.29
Price/Median PS Value 2.02
AGN's Price/Median PS Value is ranked lower than
87% of the 624 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.18 vs. AGN: 2.02 )
Ranked among companies with meaningful Price/Median PS Value only.
AGN' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.67  Med: 1.35 Max: 5.54
Current: 2.02
0.67
5.54
Price/Graham Number 1.64
AGN's Price/Graham Number is ranked higher than
63% of the 445 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.13 vs. AGN: 1.64 )
Ranked among companies with meaningful Price/Graham Number only.
AGN' s Price/Graham Number Range Over the Past 10 Years
Min: 1.55  Med: 2.54 Max: 21.84
Current: 1.64
1.55
21.84
Earnings Yield (Greenblatt) (%) -2.13
AGN's Earnings Yield (Greenblatt) (%) is ranked lower than
75% of the 738 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.20 vs. AGN: -2.13 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
AGN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -2.13  Med: 6.30 Max: 12.3
Current: -2.13
-2.13
12.3
Forward Rate of Return (Yacktman) (%) 10.14
AGN's Forward Rate of Return (Yacktman) (%) is ranked lower than
57% of the 315 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.27 vs. AGN: 10.14 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
AGN' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -1  Med: 8.40 Max: 16.2
Current: 10.14
-1
16.2

More Statistics

Revenue(Mil) $18276
EPS $ 8.86
Beta1.39
Short Percentage of Float1.47%
52-Week Range $212.67 - 340.34
Shares Outstanding(Mil)394.69

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 16,950 18,500 20,277
EPS($) 14.78 18.03 20.88
EPS without NRI($) 14.78 18.03 20.88

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:NYSE:TEVA, TSE:4502, BOM:524715, NYSE:ZTS, NAS:MYL » details
Traded in other countries:A60.Germany, AGN N.Mexico,
Allergan PLC, formerly known as Actavis PLC was incorporated in Ireland on May 16, 2013. It is an integrated specialty pharmaceutical company. The Company is engaged in development, manufacturing, marketing, sale and distribution of generic, branded generic, brand name, biosimilar and over-the-counter pharmaceutical products. It also develops and out-license generic pharmaceutical products in Europe through its Medis third-party business. It operates in three segments, Pharma, Specialty Brands and Anda Distribution. The Pharma segment includes off-patent pharmaceutical products that are therapeutically equivalent to proprietary products. The Specialty Brands segment includes patent-protected products and certain trademarked off-patent products that the Company sells and markets as brand pharmaceutical products. The Anda Distribution segment distributes generic and brand pharmaceutical products manufactured by third parties, as well as by the Company to independent pharmacies, pharmacy chains, pharmacy buying groups and physicians' offices. It competes with generic manufacturers of pharmaceutical products. It is subject to extensive, complex and evolving regulation by the federal government, the FDA, and to a lesser extent, by the U.S. Drug Enforcement Administration Occupational Safety and Health Administration and state government agencies, as well as by various regulatory agencies in foreign countries where its products or product candidates are being manufactured and/or marketed. The Federal Food, Drug and Cosmetic Act, the Controlled Substances Act and other federal statutes and regulations govern or influence the testing, manufacturing, packing, labeling, storing, record keeping, safety, approval, advertising, promotion, sale and distribution of its products.
» More Articles for NYSE:AGN

Headlines

Articles On GuruFocus.com
Jerome Dodson Sells Stake in Citrix Systems in 1st Quarter Apr 28 2016 
Weitz Funds Comments on Allergan Apr 25 2016 
Pfizer-Allergen Merger Deal End Hurts Some Funds But Helps Many Apr 08 2016 
Wilbur Ross Denounces Anti-Business 'Terrible Populist Sentiment' on CNBC Apr 07 2016 
2 Major Mergers Come to End After Tough Stance From Regulators Apr 07 2016 
Time To Buy Allergan Apr 06 2016 
Dan Loeb's Third Point Portfolio Highly Concentrated Apr 01 2016 
Daniel Loeb's Third Point Portfolio Highly Concentrated Mar 31 2016 
The Bromance at the Heart of the Valeant Disaster Mar 29 2016 
Jana Partners Trims Qualcomm Holding by 67% Mar 24 2016 

More From Other Websites
U.S. Stocks Sputter to April's End Apr 29 2016
What to Look For When Pfizer (PFE) Posts Q1 Results Apr 29 2016
Allergan Gets Positive Opinion From EU's CHMP For Its ENZEPI Apr 29 2016
Allergan Receives CHMP Positive Opinion For ENZEPI® (Pancrelipase) For Patients With Exocrine... Apr 29 2016
9:09 am Allergan confirms the CHMP adopted a Positive Opinion for the Marketing Authorisation of... Apr 29 2016
Allergan Receives CHMP Positive Opinion For ENZEPI® (Pancrelipase) For Patients With Exocrine... Apr 29 2016
Shareholders criticize Pfizer after scrapped Allergan deal Apr 28 2016
Shareholders criticize Pfizer after scrapped Allergan deal Apr 28 2016
Is Allergan On The Prowl For New Deals? Apr 27 2016
Near Mine Exploration Yields Success At Asanko Gold Mine Apr 27 2016
Allergan Is About to Enter a Low-Risk Buy Zone Apr 27 2016
Near Mine Exploration Yields Success at Asanko Gold Mine Apr 27 2016
Treasury Department Was 'Targeting' Pfizer-Allergan Deal Apr 26 2016
With New Treasury Department Rules, Is This the End of Tax Inversion Deals? Apr 26 2016
Tax Inversions: Explaining What They Are, How We Got Here and What's Next Apr 26 2016
Allergan Presents Data at the Association for Research in Vision and Ophthalmology (ARVO) Annual... Apr 26 2016
Allergan Presents Data at the Association for Research in Vision and Ophthalmology (ARVO) Annual... Apr 26 2016
Cramer: Papa's Got a Brand New Bag, and Leaves Perrigo Holding the Old One Apr 26 2016
Allergan Breaks Ground on $200 Million Waco Facility Expansion Apr 25 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK